Retatrutide also shows great potential for treating T2D in the phase 2 trial, it showed superior efficacy to dulaglutide 1.5 mg, a widely used GLP-1 RA with proven cardiovascular benefits, in reducing HbA1c and bodyweight
2,3 Correction of deficiency different routes of administration Depending on the cause of the deficiency, different strategies to correct it can be applied, although in conventional medical practice the most common treatment is intramuscular (i.m.) injection of B12
The diversity of glycosylation present on mucins is vast and complexdepending on cell type, tissue type, and disease state (Harris et al., 2024)
Then theres the hair use case
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA